Such a new qualitative achievement would not have been possible had it not been for the UAE leadership's keenness to proactively address the pandemic. Where MoHAP has approved the emergency use of a highly effective new treatment for COVID-19, becoming the first country in the world to both license and enable immediate patient use.

Endorsed by the U.S. Food and Drug Administration, the new treatment, from globally-leading healthcare company GSK, "Sotrovimab (Vir-7831)" offers the prospect of reducing hospitalization for more than 24 hours and fatalities by as much as 85% when administered to patients as an early treatment for COVID-19.

This achievement is yet another breakthrough that crowns the painstaking efforts made by our wise leadership, which spares no effort to harness all capabilities and resources to protect the health of UAE people and safeguard the country's gains achieved over the course of the past years at all levels. Where the discovery of innovative solutions and treatments in order to deliver distinct and effective health care services, especially during pandemics, can help governments face health crises more effectively and efficiently.

The new drugs, which have been approved after proving effective in treating the new variants of Coivd-19, will help speed up the recovery of infected people and reduce deaths among Covid-19 patients. It will be a turning point in the ongoing battle against the coronavirus in light of the noticeable progress made by the UAE in providing vaccines and treatments, something which resulted in tangible results including the increase in Covid-19 recoveries and the significant decrease in Covid-19 deaths.

H.E Dr. Mohamed Salim Al Olama, 

Under-Secretary at Ministry of Health and Prevention

EHS Head of Board of Directors